Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lachlan R Gray

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of Neurovirology|January 6, 2016
Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cellsLachlan R Gray, Hung On, Emma Roberts, et al.
AIDS (London, England)|December 19, 2018
HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversalMichael A Moso, Jenny L Anderson, Samantha Adikari, et al.
Retrovirology|April 23, 2013
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsMichael Roche, Hamid Salimi, Renee Duncan, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of Neurovirology|January 6, 2016
Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cellsLachlan R Gray, Hung On, Emma Roberts, et al.
AIDS (London, England)|December 19, 2018
HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversalMichael A Moso, Jenny L Anderson, Samantha Adikari, et al.
Retrovirology|April 23, 2013
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsMichael Roche, Hamid Salimi, Renee Duncan, et al.
Pageof 3